In Vivo Efficacy Articles & Analysis: Older
14 news found
In light of the growing needs of customers for novel antiviral and antibacterial compounds to treat infectious diseases, Creative Diagnostics is leveraging its expertise to perform in vitro testing for compounds, thus, estimating their potential efficacies using in vivo models. If you have questions regarding the Microneutralization Assay Service or other In ...
Confronting the growing demands for new antiviral and antimicrobial compounds as treatments for infectious diseases, Creative Diagnostics spares no effort to test these compounds in vitro to determine potential efficacy within in vivo models. If you need more information regarding the Fluorometric Neuraminidase Assay Service or have any questions related to the ...
The implication of this precise control is the maintenance of adequate and efficacious drug levels over the entire dosage interval. Starton’s previous in vivo studies demonstrated superior efficacy with continuous SC administration compared to once daily dosing in a multiple myeloma model. ...
The investigational product must be established to possess antiviral activity at concentrations achievable in vivo without causing toxic effects on cells. Furthermore, in cell culture models, the apparent antiviral activity of the investigational product may be the result of host cell death following exposure to the product. ...
In preclinical studies, it demonstrated a favorable profile with good in vivo efficacy at low doses and its observed efficacy is independent of co-administration with CYP3A4/Pgp inhibitor (e.g. ...
The company will now assess in-vitro and in-vivo efficacy of a novel method of using its technology for PD and progress thereafter into pre-clinical development. ...
Both products have also been validated and mechanistically characterised pre-clinically through in vivo efficacy data and ex vivo human cell data. The funds will also be used to expand Microbiotica’s discovery pipeline of biomarkers and LBTs in new disease areas. ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). ...
New data presented in the winning poster, titled: “GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability Data” demonstrated complete tumor regression and high tolerability of SYNtecan E™ based ADCs, and underscores the ability of Synaffix’s technologies to ...
Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company ...
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, ...
This expertise includes an extensive background in in vivo efficacy, pharmacodynamics, pharmacokinetic studies, biodistribution studies, toxicology studies, drug combination studies and natural products. ...
Initial pre-clinical studies in Parkinson’s and MSA animal models have demonstrated the ability to halt disease progression and alleviate symptoms in vivo, effectively preventing the disease from causing further damage by stopping the accumulation of pathological protein aggregates in the brain. ...
Funding will support the demonstration of the in vivo efficacy and safety of novel therapeutic chicken antibodies generated by Immune Biosolutions’ proprietary Nebula™ Platform. ...